Inhibrx — Investor Presentation (January 2021)
31 slides from Inhibrx's investor presentation, Jan 5, 2021
Slide 1: Outcomes Focused Innovation Driven January 2021
Outcomes Focused Innovation Driven January 2021
Slide 2: Presentation disclaimer
2 This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminol
Slide 3: Key investment highlights
3 Key investment highlights Proprietary single domain antibody (sdAb) platform Potential rapid path to first approval and financial sustainability Experienced leadership team aligned with investors Validation from industry leading partnersFour clinical programs with upcoming readouts
Slide 4: Four differentiated clinical programs addressing large market opportunities
4 Four differentiated clinical programs addressing large market opportunities INBRX-109 Tetravalent DR5 agonist + Single agent activity in difficult to treat tumors + Potential rapid path to approval in chondrosarcoma, registration study starting in mid 2021 + First combination cohorts initiated INB
Slide 5: Inhibrx's modular sdAb platform
5 Inhibrx’s modular sdAb platform 75 kDa 90 kDa 105 kDa 120 kDa 135 kDa 75 kDa 90 kDa 105 kDa 120 kDa 135 kDa Inhibrx multivalent formats Inhibrx multispecific formats Precision engineering Readily manufactured at high yields using standard processes Versatile and innovative formats enable validated
Slide 6: INBRX-109 Tetravalent DR5 Agonist
INBRX-109 Tetravalent DR5 Agonist
Slide 7: Death receptor target overview
7 Death receptor 5 target overview Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) DR5 activation naturally eliminates damaged and neoplastic cells Higher order clustering of DR5 is required to drive signaling Potential to treat cancers th
Slide 8: Valency drives DR5-mediated apoptosis
8 Valency drives DR5-mediated apoptosis INBRX-109 is 100x more potent in preclinical assays compared to first generation bivalent and trivalent agonists Impact of valency on DR5 induced tumor cell death 1 10 25 50 75 100 % V ia bi lit y 0 Concentration (nM) 10-110-210-310-410-5 TRAIL (Trivalent) INB
Slide 9: INBRX-109 engineered to avoid hepatotoxicity
9 INBRX-109 engineered to avoid hepatotoxicity Tetrameric INBRx-109 did not induce hepatic cell apoptosis; lacks sites for PE-ADAs mediated crosslinking Human hepatocyte toxicity assay Hepatocytes may be subject to on-target toxicity for DR5 pathway agonism Previous tetravalent DR5 agonist failed in
Slide 10: Ph1 INBRX-109 trial design and status
10 Ph1 INBRX-109 trial design and status Chondrosarcoma Synovial sarcoma Colorectal adenocarcinoma 20 PART 2: Dose expansion cohorts Initial expansion cohort indications were selected based on in vitro and in vivo sensitivities to the DR5 pathway and clinical data from prior DR5 agonists PART 3: Com
Slide 11: Chondrosarcoma fast to market opportunity
11 Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) Efficacy data PFS 3.7 mo vs 2.9 mo Placebo Comment Negative study Fast to market opportunity ~1,400 cases per year Incidence rate of ~1 in 200,000 persons per year USA Worldwide Chondrosarcoma PFS from failed study *The figures
Slide 12: INBRX-109 data and registration-enabling study design in chondrosarcoma
12 INBRX-109 data and registration-enabling study design in chondrosarcoma INBRX-109 in chondrosarcoma: Cut point 17-Oct-2020, study ongoing Disclaimer: Per investigator assessments, not confirmed by central radiology review, and data subject to change ► Ongoing PR=Partial Response, SD=Stable Diseas
Slide 13: INBRX-109 potential in multiple indications
13 INBRX-109 potential in multiple indications INITIAL INDICATIONS STUDIES INITIATED IN Q3 OF 2020 FUTURE POTENTIAL OPPORTUNITIES Mesothelioma Chemotherapy combination or single agent Pancreatic – 2nd line FOLFIRI Mesothelioma Cis-/Carboplatin & Pemetrexed Synovial sarcoma Solid tumors + IAP antagon
Slide 14: INBRX-106 Hexavalent OX40 Agonist
INBRX-106 Hexavalent OX40 Agonist
Slide 15: INBRX-106 hexavalent OX40 agonist
15 INBRX-106 hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T-cells Hexavalent engagement of OX40: • Provides co-stimulation to activated T-cells • Reverses regulatory T-cell induced immune suppression • Enhances T-cell functionality; additional benefit in combination with PD
Slide 16: INBRX-106 is a best-in-class OX40 agonist
16 INBRX-106 is a best-in-class OX40 agonist INBRX-106 incorporates all known attributes for optimal OX40 agonism - Increased valency and effector enabled Fc domain have both been empirically shown to promote activity - Lack of ligand blocking activity may provide APC activation and natural cellular
Slide 17: Hexavalent OX40 agonism potently induces anti-tumor immune activation
17 Hexavalent OX40 agonism potently induces anti-tumor immune activation Hexavalent OX40 agonism impacts multiple cell populations to tip the balance toward tumor eradication Redmond lab Earle A. Chiles Research Institute Providence Cancer Institute
Slide 18: INBRX-106 trial design and status
18 Phase 1 INBRX-106 trial design and status Initial data from Part 1 PARTS 2 & 4: Expansion cohorts INBRX-106 (Multiple dosing schedules) PARTS 1 & 3: Dose escalation finished Dec 2020 - Dose escalation in combination with Keytruda™ initiated - Signs of single agent activity, including prior PD-1 f
Slide 19: INBRX-105 PD-L1 x 4-1BB Multispecific
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 20: INBRX-105 tumor-targeted 4-1BB agonist
20 INBRX-105 tumor-targeted 4-1BB agonist 41BB agonism boosts anti-tumor T-cell activity INBRX-105, a PD-L1 dependent 4-1BB agonist: • Provides potent PD-1/PD-L1 blockade • 4-1BB agonism only at sites of PD-L1 expression, provides local co-stimulation to TILs • Engineered to avoid hepatoxicity liabi
Slide 21: INBRX-105 reversed suppression by PD-L1
21 INBRX-105 reversed suppression by PD-L1 *synthesized from sequences disclosed in WO 2018/056821 MCLA-145 analog* displayed ~20 fold reduction in potency Data indicated potential advantage of bivalent PD-L1 binding and blockade INBRX-105 potently reversed PD-L1/PD-1 suppression with activity equiv
Slide 22: INBRX-105 trial design and status
22 Phase 1 INBRX-105 trial design and status First in human Phase 1 trial started Feb. 2019 PART 1: Dose escalation INBRX-105 ongoing Locally advanced or metastatic solid tumors PDL1+ NSCLC PDL1+ Melanoma PDL1+ Basket PART 4: Dose expansion INBRX-105 + Keytruda™ planned N=20 N=20 N=20 80 patient com
Slide 23: INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
Slide 24: AATD and current therapy shortcomings
24 AATD and current therapy shortcomings AAT Serum levels in patients receiving weekly pdAAT Opportunity: The global AATD augmentation therapy market size was valued at $1.1B annually in 2018 and projected to reach $1.9B by the end of 2026 What is AATD? AATD is an orphan respiratory inherited diseas
Slide 25: INBRX-101 optimizing AAT augmentation therapy
25 INBRX-101 optimizing AAT augmentation therapy AAT Half life extension mutations Elimination of oxidation-prone residues Fc INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein • Potential to extend the dosing range, from weekly to every three weeks, while maintaining patien
Slide 26: INBRX-101: first human pharmacokinetic data
26 INBRX-101: first human pharmacokinetic data PK profile of first 5 patients: 10 mg/kg INBRX-101 Predicted mean serum AAT levels: 120 mg/kg of INBRX-101 every 3 weeks Preliminary human PK data for first five subjects dosed with 10 mg/kg single IV dose of INBRX-101 • Consistent with preclinical esti
Slide 27: Near term expected clinical milestones
27 H2 2020 H1 2021 H2 2021 Near term expected clinical milestones INBRX-109 (DR5) registration-enabling trial initiation- chondrosarcoma INBRX-101 (AAT) Phase 1 data INBRX-105 (PDL-1x41BB) dose escalation data INBRX-105 (PDL-1x41BB) expansion cohort data INBRX-109 (DR5) Chondrosarcoma updated data a
Slide 28: 11025 N. Torrey Pines Rd, Ste La Jolla, CA 92037 www.inhibrx.com
11025 N. Torrey Pines Rd, Ste 140 La Jolla, CA 92037 www.inhibrx.com
Slide 29: Supplementary Slides
Supplementary Slides
Slide 30: INBRX-109 data in malignant pleural mesothelioma
30 INBRX-109 data in malignant pleural mesothelioma Cut point 17-Oct-2020, study ongoing Disclaimer: Per investigator assessments, not confirmed by central radiology review, and data subject to change PR=Partial Response, SD=Stable Disease, PD=Progressive Disease, NE=Not Evaluable ► Ongoing *Off-stu
Slide 31: INBRX-109 - favorable Adverse Event (AE) profile
31 INBRX-109 - favorable Adverse Event (AE) profile AE Term AE related to INBRX-109 (very likely, probable, possible) Grade per CTCAEv5.0 Gr1&2 (N) Gr1&2 (%) Gr=/>3 (N) Gr=/>3 (%) All Grade (N) All Grade (%) Fatigue 14 18 0 0 14 18 AST increased 7 9 3 4 10 13 ALT increased 7 9 3 4 10 13 Nausea 6 8 1